Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease

Archives of Neurology

Volumn 54, Issue 4, 1997, Pages 465-473

  Bodick, Neil C ^a   Offen, Walter W ^a   Levey, Allan I ^b   Cutler, Neal R ^c   Gauthier, Serge G ^d   Satlin, Andrew ^e   Shannon, Harlan E ^a   Tollefson, Gary D ^a   Rasmussen, Kurt ^a   Bymaster, Frank P ^a   Hurley, Daniel J ^g   Potter, William Z ^a   Paul, Steven M ^a,f  

^a ELI LILLY AND COMPANY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CALIFORNIA CLINICAL TRIALS   (United States)

^d MCGILL UNIVERSITY   (Canada)

^e MCLEAN HOSPITAL   (United States)

^f INDIANA UNIVERSITY   (United States)

^g Lilly Corporate Center ^*

Author keywords

[No Author keywords available]

Indexed keywords

MUSCARINIC M1 RECEPTOR; MUSCARINIC M4 RECEPTOR; XANOMELINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BEHAVIOR; CLINICAL FEATURE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DIGESTIVE SYSTEM FUNCTION DISORDER; DOPAMINERGIC ACTIVITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SINGLE BLIND PROCEDURE; SYNCOPE;

EID: 0030902127     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.1997.00550160091022     Document Type: Article

References (58)

1. Reisberg B, Borenstein J, Salob S, Ferris SH, Franssen E, Georgotas A. Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. J Clin Psychiatry. 1987;48(suppl 5):9-15.
2. Drevets WC, Rubin EH. Psychotic symptoms and the longitudinal course of senile dementia of the Alzheimer type. Biol Psychiatry. 1989;25:39-48.
3. Teri L, Borson S, Kiyak HA, Yamagishi M. Behavioral disturbance, cognitive dysfunction, and functional skill: prevalence and relationship in Alzheimer's disease. J Am Geriatr Soc. 1989;37:109-116.
4. Wragg RE, Jeste DV. Overview of depression and psychosis in Alzheimer's disease. Am J Psychiatry. 1989;146:577-587.
5. Gilley DW, Wilson RS, Bennett DA, Bernard BA, Fox JH, Predictors of behavioral disturbance in Alzheimer's disease. J Gerontol B Psychoi Sci Soc Sci. 1991;46:362-371.
6. Rosen J, Zubenko GS. Emergence of psychosis and depression in the longitudinal evaluation of Alzheimer's disease. Biol Psychiatry. 1991;29:224-232.
7. Deutsch LH, Bylsma FW, Rovner BW, Steele C, Folstein MF. Psychosis and physical aggression in probable Alzheimer's disease. Am J Psychiatry, 1991;148:1159-1163.
8. Davies P. Neurotransmitter-related enzymes in senile dementia of the Alzheimer type. Brain Res. 1979;171:319-327.
9. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delong MR. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science. 1982;215:1237-1239.
10. Wilcox GK, Esiri MM, Bowen DM, et al. Alzheimer's disease: correlation of cortical choline acetyltransferase activity with the severity of dementia and histolopical abnormalities. J Neurol Sci. 1982;57:407-417.
11. Coyle JT, Price DL, Delong MR. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science. 1983;219:1184-1190.
12. DeKosky ST, Harbaugh RE, Scbmitt FA, et al. Cortical biopsy in Alzheimer's disease: diagnostic accuracy and neurochemical, neuropathological, and cognitive correlates. Ann Neurol. 1992;32:625-632.
13. Farlow M, Gracon SI, Hershey LA, Lewis KW, Sadowsky CH, Dolan-Ureno J. A controlled trial of tacrine in Alzheimer's disease. JAMA. 1992;268:2523-2529.
14. Davis KL, Thai LJ, Gamzu ER, et al. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. N Engl J Med. 1992;327:1253-1259.
15. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA. 1994;271:985-991.
16. Growdon JH. Treatment for Alzheimer's disease? N Engl J Med. 1992;327: 1306-1308.
17. Cummings JL, Kaufer D. Neuropsychiatrie aspects of Alzheimer's disease: the cholinergic hypothesis revisited. Neurology. 1966;47:876-883.
18. Raskind MA, Peskind ER. Neurobiologic bases of noncognitive behavioral problems in Alzheimer disease. Alzheimer Dis Assoc Disord. 1994;8(suppl 3):54-60.
19. Bonner TI, Buckley NJ, Young AC, Brann MR. Identification of a family of muscarinic acetylcholine receptor genes. Science. 1987;237:527-532.
20. Hulme EC, Birdsall NJM, Buckley NJ. Muscarinic receptor subtypes. Annu Rev Pharmacol of Toxicol. 1990;30:633-673.
21. McKinney M, Coyle JT. Subject review: the potential for muscarinic receptor subtype-specific pharmacotherapy for Alzheimer's disease. Mayo Clinic Proc. 1991;66:1225-1237.
22. 1 muscarinic agonists: progress and perspectives in new muscarinic agonists. Drug News Perspect. 1994;7:453-464.
23. Mrzljak L, Levey AI, Goldman-Rakic PS. Association of m1 and m2 muscarinic receptor proteins with asymmetric synapses in the primate cerebral cortex: morphological evidence for cholinergic modulation of excitatory neurotransmission. Proc Natl Acad Sci U S A. 1993;90:5194-5198.
24. Levey AI, Kitt CA, Simonds WF, Price DL, Brann MR. Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtypespecific antibodies. J Neurosci. 1991;11:3218-3226.
25. Flynn DD, Ferrari-DiLeo G, Mash DC, Levey AI. Rapid communication: differential regulation of molecular subtypes of muscarinic receptors in Alzheimer's disease. J Neurochem. 1995;64:1888-1891.
26. Winkler J, Suhr ST, Gage FH, Thal LJ, Fisher LJ. Essential role of neocortical acetylcholine in spatial memory. Nature. 1995;375:484-487.
27. Giacobini E. Cholinergic receptors in human brain: effects of aging and Alzheimer's disease. J Neurosci Res. 1990;27:548-560.
28. Sversson AL, Alufusoff I, Nordberg A. Characterization of muscarinic receptor subtypes in Alzheimer and control brain cortices by selective muscarinic antagonists. Brain Res. 1992;396:142-148.
29. Mash DC, Flynn DD, Potter LT. Loss of M2 muscarine receptors in the cerebral cortex in Alzheimer's disease and experimental cholinergic denervation. Science. 1985;228:1115-1117.
30. Davis R, Raby C, Callahan MJ, et al. Subtype selective muscarinic agonists: potential therapeutic agents for Alzheimer's disease. Prog Brain Res. 1993;98:439-445.
31. Yasuda RP, Ciesla W, Flores LR, et al. Development of antisera selective for m4 and m5 muscarinic cholinergic receptors: distribution of m4 and m5 receptors in rat brain. Mol Pharmacol. 1993;43:149-157.
32. Bernard V, Normand E, Bloch B. Phenotypical characterization of the rat striatal neurons expressing muscarinic receptor genes. J Neurosci 1992;12:3591-3600.
33. Selkoe DJ. Alzheimer's disease: a central role for amyloid. J Neuropathol Exp Neurol. 1994;43:438-447.
34. Lorenzo A, Yankner BA. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by Congo red. Proc Natl Acad Sci USA. 1994:91:12243-12247.
35. Nitsch RM, Slack BE, Wurtman RJ, Growdon JH. Release of Alzheimer's amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science. 1992;258:304-307.
36. DeLapp NW, Eckols K, Bymaster FP, Mitch CH, Shannon HE, Ward JS. The muscarinic M1 agonist xanomeline increases soluble amyloid precursor protein release from Chinese hamster ovary-m1 cells. Life Sci. 1995;57:1183-1190.
37. Bymaster FP, Wong DT, Mitch CH, et al. Neurochemical effects of the M1 muscarinic agonist xanomeline (LY246708/NNC11-0232). J Pharmacol Exp Ther. 1994;269:282-289.
38. 1 receptors. J Pharmacol Exp Ther. 1994;269:271-281.
39. Bymaster FP, Whitesitt CA, Shannon HE. Xanomeline: a selective muscarinic agonist for the treatment of Alzheimer's disease. Drug Dev Res. In press.
40. Farde L, Suhara T, Halldin C, et al. New radioligands for PET-examination of central muscarinic receptors. Presented at the Alzheimer's and Parkinson's Diseases Recent Developments Third International Conference; November 1-6, 1993; Chicago, III.
41. Bodick NC, DeLong AF, Bonate PL, Gillespie T, Henry DP, Satterwhite JH. Xanomeline, a specific ml agonist: early clinical studies. In: Giacobini E, Becker R, eds. Alzheimer Disease: Therapeutic Strategies. Cambridge, Mass: Birkhauser Boston Inc; 1994:234-238.
42. Sramek JJ, Hurley DJ, Wardle TS, et al. The safety and tolerance of xanomeline tartrate in patients with Alzheimer's disease. J Clin Pharmacol. 1995;35:800-806.
43. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944.
44. Folstein MF, Folstein SE, McHugh PR. 'Mini-Mental State': a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
45. Mohs RC, Cohen L. Alzheimer's Disease Assessment Scale (ADAS). Psychopharmacol Bull. 1988;24:627-628.
46. Veroff AE, Cutler NR, Sramek JJ, et al. A new assessment tool for neuropsychopharmacologic research: the computerized neuropsychological test battery. J Geriatr Psychiatry Neurol. 1991;3:211-217.
47. Knopman DS, Knapp MJ, Gracon SI, Davis CS. The Clinician Interview-Based Impression (CIBI): a clinician's global change rating scale in Alzheimer's disease. Neurology. 1994;44:2315-2321.
48. Spiegel R, Brunner C, Ermini-Fünfschilling D, et al. A new behavioral assessment scale for geriatric out- and in-patients: the NOSGER (Nurses' Observation Scale for Geriatric Patients). J Am Geriatr Soc. 1991;39:339-447.
49. Ferris SH, Steinberg G, Shulman E, et al. Institutionalization of Alzheimer's patients: reducing precipitating factors through family counseling. Arch Found Thanatol. 1985;12:7.
50. Reisberg B, Borenstein J, Franssen E, Shulman E, Steinberg G, Ferris SH. Remediable behavioral symptomatology in Alzheimer's disease. Hosp Community Psychiatry. 1986;37:1199-1201.
51. Teri L, Rabins P, Whitehouse P, et al. Management of behavior disturbance in Alzheimer disease: current knowledge and future directions. Alzheimer Dis Assoc Disord. 1992;6:77-88.
52. Platt JE, Campbell M, Green WH, Perry R, Cohen IL. Effects of lithium carbonate and haloperidol on cognition in aggressive hospitalized school-age children. J Clin Psychopharmacol. 1981;1:8-13.
53. Cummings JL, Gorman DG, Shapira J. Physostigmine ameliorates the delusions of Alzheimer's disease. Biol Psychiatry. 1993;33:536-541.
54. Chiodo LA, Buney BS. Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. J Neurosci. 1983;3:1607-1619.
55. White FJ, Wang RY. Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science. 1983;221:1054-1057.
56. Stockton ME, Rasmussen K. Electrophysiological effects of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamine neurons. Neuropsychopharmacology. 1994;14:97-104.
57. Lipsitz L, Bodick N, Goldberger AL, MacMahon M, Medina A. Effects of central muscarinic-1 receptor stimulation on blood pressure regulation. Hypertension. In press.
58. Mega MS, Cumrnings JL, Fiorello T, Gornbein J. The spectrum of behavioral changes in Alzheimer's disease. Neurology. 1996;46:130-135.